Lates News

According to Every Today AI News, Dongwu Securities released a research report on September 12, giving Jingsen Pharmaceutical (002020.SZ) a buy rating. The reasons for the rating mainly include: 1) The research pipeline of new drugs is gradually becoming more abundant, and small molecule LP (a) inhibitors have the potential to go global; 2) The insomnia drug Daiduoxin has been listed and trading volume has increased significantly, contributing to an increase in performance; 3) Existing business maintains steady growth, and blockbuster first generics such as Calilazine will contribute to future growth. (Daily Economic News)